Phillips-Medisize Signs Supply Agreement with Sanofi
News Feb 08, 2014
Phillips-Medisize Corp. has announced that it has signed a supply agreement for insulin pen components with Sanofi, a leader for diabetes treatment. As a result, injection pen component production at the plant in Kontiolahti, Finland, has been expanded with an automated production line.
Given the successful production by Phillips-Medisize of insulin pen components for many years, this new project was assigned to the Kontiolahti plant and underlines the long-term partnership between Phillips-Medisize and Sanofi.
The new pen is an easy-to-use disposable pen for the administration of lixisenatide. The finished device is made for the Japanese market and meets the stringent quality demand from that country.
Phillips-Medisize has fulfilled the manufacture requirements due to its premium expertise in assembly technology. The manufacturing involves injection molding technology, assembly and tray handling robots, various measuring and testing systems as well as pad printing.
The complex and highly automated assembly line was planned and installed by Phillips-Medisize, and includes multiple camera inspection points in the process. The company also built the required molds, which were principally designed and produced in the company’s in-house tool shop.
Phillips-Medisize implemented the project, including all validations required, and delivered validated product in less than 12 months. The final pen assembly will be launched out by Sanofi in Frankfurt, Germany.
Phillips-Medisize President and CEO, Matt Jennings says, "This agreement confirms our in-house tooling and automation expertise, combined with excellent project management capabilities are highly valued by our customers. We will continue to develop our competency to offer them an even quicker service for their drug delivery device projects and are delighted to contribute to the rapid growth of the Sanofi diabetes treatment business."
In February 2013, Phillips-Medisize added another 6000 m² (64,583 ft²) capacity to its Finnish facility. The expansion was driven by new opportunities the company has been awarded, as well as, to support increased global demand for devices with precise dosage drug delivery requirements.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018